Incyte beats Q2 revenue estimates on strong product demand
INCY•Demand growth and higher expenses
The company said increased demand for Jakafi, Opzelura, excluding the one-time benefit, and Hematology/Oncology products such as Niktimvo, Monjuvi/Minjuvi, and Zynyz contributed to underlying sales growth.
Operating expenses rose due to increased R&D investment in late-stage assets and higher SG&A spending on marketing and pre-launch activities.
Q2 revenue and EPS beat estimates
Incyte said second-quarter total revenue rose 38% year over year, beating analyst expectations. Adjusted EPS for the quarter also beat analyst expectations.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Total Revenue | Beat | $1.67 bln | $1.47 bln (19 Analysts) |
| Q2 Adjusted EPS | Beat | $3.09 | $2.10 (18 Analysts) |
| Q2 EPS | $2.81 | ||
| Q2 Adjusted Operating Income | Beat | $773.04 mln | $549.44 mln (12 Analysts) |
Analyst view and valuation context
The current average analyst rating on the shares is "buy," with 12 "strong buy" or "buy" ratings, 15 "hold" ratings and no "sell" or "strong sell" ratings.
The median 12-month price target for Incyte Corp is $112.00, about 5.8% below its July 27 closing price of $118.87. The stock recently traded at 14 times the next 12-month earnings versus a P/E of 12 three months ago.
Guidance raised after Opzelura settlement boost
The company raised 2026 full-year net sales guidance after a CMS settlement boosted Opzelura sales.
